论文部分内容阅读
目的:研究早期连续性静脉-静脉血液滤过和反复间断静脉一静脉血滤治疗重症急性胰腺炎的临床价值。方法:45例SAP患者随机分为CVVH组(25例)和RIVVH组(20例)。比较2组患者的生命体征、生化指标、治疗前后的APACHEⅡ评分、死亡率、好转率。结果:CVVH组中3例死于MODS,死亡率为12%,RIVVH组死亡3例(15%),其差异有统计学意义(P<0.05);CVVH组好转率为80%(20/25),与RIVVH组的80%(16/20)一致。在治疗的早期阶段,对于改善生命体征,降低APACHEⅡ评分CVVH效果更显注,但随着治疗时间的延长,这种差异逐渐变小,在后期两组间不再存在疗效差异,最终疗效上没有明显的差异,而RIVVH组,在治疗费用和人员成本上具有优势。结论:早期RIVVH治疗SAP可以作为SAP重要的辅助治疗措施。
Objective: To study the clinical value of early continuous veno-venous hemofiltration and repeated interrupted veno-venous hemofiltration in the treatment of severe acute pancreatitis. Methods: Forty-five SAP patients were randomly divided into CVVH group (n = 25) and RIVVH group (n = 20). The vital signs, biochemical indexes, APACHEⅡscore before and after treatment, mortality and improvement rate were compared between the two groups. Results: In the CVVH group, 3 patients died of MODS, the mortality rate was 12%, and 3 patients died in the RIVVH group (15%), the difference was statistically significant (P <0.05); The CVVH rate was 80% (20/25 ), Consistent with 80% (16/20) of the RIVVH group. In the early stage of treatment, the effect of reducing APACHEⅡscore CVVH was more significant for improving vital signs, but with the extension of treatment time, the difference gradually became smaller. There was no difference in efficacy between the two groups in the early stage of treatment, and the final curative effect was not Significant differences were found in the RIVVH group, which had advantages in terms of treatment costs and staff costs. Conclusion: Early RIVVH treatment of SAP can be an important adjuvant treatment of SAP.